Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > VCNX Vaccinex > Detailed Quotes

VCNX Vaccinex

Watchlist
1.040
-0.040-3.70%
Close 07/01 16:00 ET
1.04000.00%
Post Mkt Price 07/01 19:50 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
1.095
Open
1.020
Turnover
66.74K
Low
1.020
Pre Close
1.080
Volume
62.95K
Market Cap
44.37M
P/E(TTM)
Loss
52wk High
2.810
Shares
42.66M
P/E(Static)
Loss
52wk Low
0.900
Float Cap
27.01M
Bid/Ask %
63.64%
Historical High
12.230
Shs Float
25.97M
Volume Ratio
1.24
Historical Low
0.900
Dividend TTM
--
Div Yield TTM
--
P/B
2.74
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.24%
Amplitude
6.94%
Avg Price
1.060
Lot Size
1
Float Cap
27.01M
Bid/Ask %
63.64%
Historical High
12.230
Shs Float
25.97M
Volume Ratio
1.24
Historical Low
0.900
Dividend TTM
--
P/B
2.74
Dividend LFY
--
Turnover Ratio
0.24%
Amplitude
6.94%
Avg Price
1.060
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington’s disease, Alzheimer’s disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
CEO: Zauderer Ph.D., Maurice
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top